Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
Turk J Med Sci. 2021 Jun 28;51(3):1146-1152. doi: 10.3906/sag-2007-243.
BACKGROUND/AIM: The presence of comorbidities in patients with acromegaly causes an increase in morbidity and/or mortality and a decrease in quality of life. In this study, we aimed to investigate the demographic, clinical and laboratory features, prevalence of acro- megaly-related comorbidities, and factors associated with these comorbidities in patients with acromegaly.
In the study, 96 patients who were followed up with the diagnosis of acromegaly were included. Clinical, labo- ratory and imaging features, and accompanying comorbidities of the patients were recorded from the patient files.
Of the patients included in the study, 63 (65.6%) were female and 33 (34.4%) were male. The mean age of diagnosis was 42.61± 12.08, and the mean follow-up period was 9.97 ± 7.26 years. Median insulin-like growth factor 1 level was 238.16 ng/mL (30.5–820), median growth hormone level was 2.05 ug/L (0.1–29.4). A total of 60 (62.5%) of the patients were in the well-controlled group, and 36 (37.5%) had active disease at the time of inclusion. Diabetes mellitus (DM) was detected in 30 (31.3%) patients, prediabetes in 19 (28.8%) patients, hypertriglyceridemia in 38 (42.2%) patients, hypertension (HT) in 41 (42.7%) patients, cardiovascular disease in 5 (5.2%) patients, malignancy in 9 (9.4%) patients, obstructive sleep apnea syndrome in 8 (8.3%) patients, carpal tunnel syndrome in 11 (11.5%) patients, arthropathy in 5 (5.2%) patients, hearing loss in 7 (7.3%) patients, thyroid nodule in 56 (67.5%) patients, thyroid cancer in 4 (4.2%) patients, colonic polyp in 19 (38.8%) patients.
In this study, we revealed that the most common comorbidities in acromegaly patients in the Turkish population are thyroid nodules, low high-density lipoprotein (HDL cholesterol (HDL-C) level, hypertriglyceridemia, HT, colonic polyps, DM, and prediabetes, and female sex and age at diagnosis are the most important factors associated with comorbidities.
背景/目的：肢端肥大症患者合并症的存在会导致发病率和/或死亡率增加，以及生活质量下降。在这项研究中，我们旨在调查肢端肥大症患者的人口统计学、临床和实验室特征、肢端肥大症相关合并症的患病率，以及与这些合并症相关的因素。
本研究共纳入 96 例诊断为肢端肥大症的患者。从患者病历中记录患者的临床、实验室和影像学特征以及伴随的合并症。
在本研究中，63 例（65.6%）为女性，33 例（34.4%）为男性。诊断时的平均年龄为 42.61±12.08 岁，平均随访时间为 9.97±7.26 年。中位胰岛素样生长因子 1 水平为 238.16ng/mL（30.5-820），中位生长激素水平为 2.05ug/L（0.1-29.4）。共有 60 例（62.5%）患者处于良好控制组，36 例（37.5%）在纳入时患有活动性疾病。30 例（31.3%）患者检测出糖尿病（DM），19 例（28.8%）患者存在糖尿病前期，38 例（42.2%）患者存在高三酰甘油血症，41 例（42.7%）患者存在高血压（HT），5 例（5.2%）患者存在心血管疾病，9 例（9.4%）患者存在恶性肿瘤，8 例（8.3%）患者存在阻塞性睡眠呼吸暂停综合征，11 例（11.5%）患者存在腕管综合征，5 例（5.2%）患者存在关节病，7 例（7.3%）患者存在听力损失，56 例（67.5%）患者存在甲状腺结节，4 例（4.2%）患者存在甲状腺癌，19 例（38.8%）患者存在结肠息肉。
在这项研究中，我们揭示了土耳其肢端肥大症患者最常见的合并症是甲状腺结节、低高密度脂蛋白（HDL）胆固醇（HDL-C）水平、高三酰甘油血症、HT、结肠息肉、糖尿病、糖尿病前期，以及女性和诊断时的年龄是与合并症相关的最重要因素。
